Adaptimmune Therapeutics PLC (ADAP)
0.6199
-0.03
(-5.26%)
USD |
NASDAQ |
Jan 08, 16:00
0.6241
0.00 (0.00%)
After-Hours: 20:00
Adaptimmune Therapeutics Enterprise Value: 22.40M for Jan. 8, 2025
View 4,000+ Financial Data Types:
Add
Browse
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
Biodexa Pharmaceuticals PLC | -3.430M |
TC BioPharm (Holdings) PLC | 2.885M |
Verona Pharma PLC | 3.565B |
Autolus Therapeutics PLC | -15.71M |
NuCana PLC | -10.68M |
Enterprise Value Related Metrics
Net Income (Quarterly) | -17.62M |
Revenue (Quarterly) | 40.90M |
Total Expenses (Quarterly) | 55.58M |
EPS Diluted (Quarterly) | -0.06 |
Profit Margin (Quarterly) | -43.07% |
Earnings Yield | -29.04% |
Normalized Earnings Yield | -29.04 |